Nurix Therapeutics, Inc. NRIX
Set alert
26.22 USD +0.52 +2.02%
As of Nov 3, 9:37 AM ET
25.70 Day range 26.28
11.67 52-week range 28.23
- YTD
- +38.22%
- 1 year
- +107.77%
- Open
- 25.72
- Prev close
- 25.70
- Mkt cap
- 2.87B
- Vol
- 49.03K
- Avg vol
- 1.74M
- EPS
- 2.43
- P/E
- 10.81
- Div yield
- 0.00%
More statistics
- Low
- 25.70
- High
- 26.28
- Forward P/E
- -20.15
- Beta
- 1.78
- Short ratio
- 10.30
- Inst. own
- 111.03%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Jan 27, 2027
- 50-d avg
- 24.98
- 200-d avg
- 20.18
- 1y target
- 34.50
30m chart
Built from the cached five-day intraday bars.
Signals (8)
| Name | Time | Ago |
|---|---|---|
| SMA: Bullish | Nov 3, 9:55 AM | just now |
| MACD: Buy Signal | Nov 2, 4:00 PM | 17 hours ago |
| SMA: Bearish | Nov 2, 9:55 AM | 23 hours ago |
| MACD: Sell Signal | Nov 2, 9:55 AM | 23 hours ago |
| MACD: Buy Signal | Oct 30, 4:00 PM | 3 days ago |
| SMA: Bullish | Oct 30, 3:25 PM | 3 days ago |
| SMA: Bearish | Oct 29, 12:55 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:55 PM | 5 days ago |
Analyst view
Consensus: none
Price target (mean) 34.50 +31.6% upside
Now 26.22
- Target (low)
- 25.00
- Target (mean)
- 34.50
- Target (high)
- 45.00
Ratings (0m) 14 13 buy · 1 hold · 0 sell
- Strong buy5
- Buy8
- Hold1
- Sell0
- Strong sell0
Recommendation trend
- This month 14
- 1 month ago 14
- 2 months ago 15
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | 1.51 | -0.64 – 5.26 | -0.82 | +283.9% | 287.86M | +2020.2% | 3 |
| Next quarter | -0.59 | -0.59 – -0.59 | -0.79 | +25.3% | 15.00M | +139.9% | 1 |
| Current year | 3.02 | 2.96 – 3.10 | -3.05 | +199.0% | 744.85M | +786.9% | 3 |
| Next year | -1.28 | -2.48 – -0.62 | 3.02 | -142.2% | 123.22M | -83.5% | 3 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 16, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Oct 13, 2026 | RBC Capital | Maintained | Outperform | Outperform |
| Oct 13, 2026 | Oppenheimer | Maintained | Outperform | Outperform |
| Oct 13, 2026 | Truist Securities | Maintained | Buy | Buy |
| Oct 13, 2026 | Baird | Maintained | Outperform | Outperform |
| Oct 13, 2026 | Needham | Reiterated | Buy | Buy |
| Aug 10, 2026 | RBC Capital | Maintained | Outperform | Outperform |
| Aug 4, 2026 | Needham | Reiterated | Buy | Buy |
| Jul 28, 2026 | Morgan Stanley | Maintained | Overweight | Overweight |
| Jul 22, 2026 | UBS | Maintained | Buy | Buy |
| Jul 13, 2026 | Mizuho | Maintained | Outperform | Outperform |
| Jul 10, 2026 | Truist Securities | Maintained | Buy | Buy |
| Jul 10, 2026 | RBC Capital | Maintained | Outperform | Outperform |
| Jul 10, 2026 | Stifel | Maintained | Buy | Buy |
| Jul 10, 2026 | BTIG | Reiterated | Buy | Buy |
| Jul 10, 2026 | Needham | Reiterated | Buy | Buy |
| Jul 10, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Jun 18, 2026 | Baird | Maintained | Outperform | Outperform |
| Jun 15, 2026 | Needham | Reiterated | Buy | Buy |
| Jun 10, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Jun 9, 2026 | Truist Securities | Maintained | Buy | Buy |
| Jun 9, 2026 | BTIG | Maintained | Buy | Buy |
| Jun 8, 2026 | Jefferies | Maintained | Buy | Buy |
| Jun 8, 2026 | Wells Fargo | Maintained | Overweight | Overweight |
| Jun 8, 2026 | Needham | Maintained | Buy | Buy |
| May 18, 2026 | BTIG | Reiterated | Buy | Buy |
| Apr 27, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Apr 23, 2026 | Needham | Reiterated | Buy | Buy |
| Apr 10, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Apr 9, 2026 | Wells Fargo | Maintained | Overweight | Overweight |